One ASO dose in mice resulted in long-term LRRK2 targeting and decreased RAB10 phosphorylation and LC3B II/I ratios, suggesting LRRK2 functional changes, and promoting ASOs as a therapeutic strategy for PD. This evidence concerns the gene LRRK2 and Parkinson disease.